SCHEMBL4116233

SCHEMBL4116233

O=C(NCCC1C(Nc2nccc(N3CCCCCC3)n2)CCCN1C1CCCCC1)c1ccccn1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 2/20 0.43
▸ HTR1A P08908 3/20 0.41
▸ HTR2A P28223 3/20 0.41
▸ HSD11B1 P28845 1/20 0.40
▸ DRD3 P35462 2/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KLF5 Q13887 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ KDR P35968 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ OGA O60502 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13696561 1.00 CXCR4 (0.43) CXCR4HTR1AHTR2AHSD11B1DRD3
SCHEMBL4105482 0.87 CXCR4 (0.40) CXCR4HSD11B1
SCHEMBL4116420 0.87 CXCR4 (0.43) CXCR4HSD11B1OGA
SCHEMBL2037748 0.87 CXCR4 (0.39) CXCR4HSD11B1KDM4E
SCHEMBL13696563 0.87 CXCR4 (0.39) CXCR4HSD11B1KDM4E
SCHEMBL13696562 0.85 ALDH1A1 (0.40) CXCR4HTR1AHTR2ADRD3NPC1
SCHEMBL2011688 0.85 ALDH1A1 (0.40) CXCR4HTR1AHTR2ADRD3NPC1
SCHEMBL4116141 0.85 CXCR4 (0.40) CXCR4HSD11B1SMN1; SMN2
SCHEMBL13696571 0.84 HRH4 (0.40) CXCR4
SCHEMBL13696552 0.83 CXCR4 (0.44) CXCR4OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US claimed
EP-1852432-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 — — EP claimed
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed
EP-1852432-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 CXCR4 1/4885HTR1A 2219/4885HTR2A 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback